Q&A With Vincenzo La Mura From University of Milan: Cirrhosis and its Benefit-Risk Ratios


Anticoagulants may not be the ideal treatment for all patients with cirrhosis and portal hypertension but research is being done to find the best possible treatments for these patients.

Vincenzo La Mura, University of Milan focused his latest research on the clinical and pathophysiological aspects associated with cirrhosis and portal hypertension to better understand which subset of patients truly benefit from anticoagulation treatment.

La Mura presented the results of his research When the European Association for the Study of Liver held its 50th Annual Liver Congress in Vienna.

Recent Videos
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
Optimizing Diabetes Therapies with New Classifications
Should We Reclassify Diabetes Subtypes?
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
© 2024 MJH Life Sciences

All rights reserved.